To include your compound in the COVID-19 Resource Center, submit it here.

BeiGene reports Phase I data for tislelizumab in urothelial carcinoma

BeiGene Ltd. (NASDAQ:BGNE) reported preliminary data from 15 evaluable patients with urothelial carcinoma in a Phase I trial showing that tislelizumab

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE